Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multi-center, Open-label, Dose Escalation, First-In-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of JSKN003 in Subjects With Advanced or Metastatic Solid Malignant Tumors

Next Previous
Trial Profile

A Phase I, Multi-center, Open-label, Dose Escalation, First-In-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of JSKN003 in Subjects With Advanced or Metastatic Solid Malignant Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JSKN 003 (Primary)
  • Indications HER2 positive breast cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Alphamab Oncology

Most Recent Events

  • 04 Jun 2024 Results (As of 15 Dec 2023, n=32 ) from dose-escalation part , presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 10 Apr 2024 Results(As of 15 Dec 2023, n=32 pts) evaluating safety, tolerability, MTD or RP2D, PK, and preliminary antitumor activity,presented at the 115th Annual Meeting of the American Association for Cancer Research
  • 13 Oct 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top